Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.
Nat Med
; 15(4): 392-400, 2009 Apr.
Article
en En
| MEDLINE
| ID: mdl-19305413
ABSTRACT
Inhibitors of alpha(v)beta(3) and alpha(v)beta(5) integrin have entered clinical trials as antiangiogenic agents for cancer treatment but generally have been unsuccessful. Here we present in vivo evidence that low (nanomolar) concentrations of RGD-mimetic alpha(v)beta(3) and alpha(v)beta(5) inhibitors can paradoxically stimulate tumor growth and tumor angiogenesis. We show that low concentrations of these inhibitors promote VEGF-mediated angiogenesis by altering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 trafficking, thereby promoting endothelial cell migration to VEGF. The proangiogenic effects of low concentrations of RGD-mimetic integrin inhibitors could compromise their efficacy as anticancer agents and have major implications for the use of RGD-mimetic compounds in humans.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Melanoma Experimental
/
Receptores de Vitronectina
/
Inhibidores de la Angiogénesis
/
Integrina alfaVbeta3
/
Neoplasias Pulmonares
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Año:
2009
Tipo del documento:
Article